¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"lymphocyte inhibitory factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • monocyte lymphocyte ratio
    ´ÜÇÙ±¸¸²ÇÁ±¸ºñÀ²
  • primed lymphocyte
    ÃÊȸ¹Î°¨¸²ÇÁ±¸
  • primed lymphocyte typing
    ÃÊȸ¹Î°¨¸²ÇÁ±¸Çü°áÁ¤
  • reticular lymphocyte
    ±×¹°¸²ÇÁ±¸, ¸Á»ó¸²ÇÁ±¸
  • sensitized lymphocyte
    ¹Î°¨È­¸²ÇÁ±¸
  • gastric inhibitory polypeptide
    À§¾ïÁ¦Æú¸®ÆéƼµå
  • hypothalamic inhibitory hormone
    ½Ã»óÇϺξïÁ¦È£¸£¸ó
  • inhibitory action
    ¾ïÁ¦ÀÛ¿ë, ÀúÁöÀÛ¿ë
  • inhibitory enzyme
    ¾ïÁ¦È¿¼Ò
  • inhibitory hormone
    ¾ïÁ¦È£¸£¸ó
  • inhibitory interneuron
    ¾ïÁ¦»çÀ̽Ű漼Æ÷, ¾ïÁ¦°³Àç´º·±
  • inhibitory postsynaptic potential
    ¾ïÁ¦½Ã³ÀÀÌÈÄÀüÀ§, ¾ïÁ¦¿¬Á¢ÀÌÈÄÀüÀ§
  • inhibitory synapse
    ¾ïÁ¦½Ã³À½º, ¾ïÁ¦¿¬Á¢
  • inhibitory transmitter
    ¾ïÁ¦Àü´Þ¹°Áú
  • minimal inhibitory concentration
    ÃÖÀú¾ïÁ¦³óµµ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡¼ºÀåÀÎÀÚ, Ç÷¼ÒÆÇ±â¿ø¼ºÀåÀÎÀÚ
  • precipitation factor
    ÃËÁø¿äÀÎ
  • predisposing factor
    ¼±Çà¿äÀÎ
  • prognostic factor
    ¿¹ÈÄÀÎÀÚ
  • psychological factor
    ½É¸®¿ä¼Ò
  • relaxing factor
    ÀÌ¿ÏÀÎÀÚ
  • resistance factor
    ³»¼ºÀÎÀÚ, °ßµõÀÎÀÚ
  • rheumatoid factor
    ·ù¸¶Æ¼½ºÀÎÀÚ
  • risk factor
    À§ÇèÀÎÀÚ
  • transforming growth factor
    Àüȯ¼ºÀåÀÎÀÚ
  • vascular endothelial growth factor
    Ç÷°ü³»ÇǼºÀåÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • inhibitory interneuron
    ¾ïÁ¦»çÀ̽Ű漼Æ÷
  • inhibitory synapse
    ¾ïÁ¦¿¬Á¢
  • inhibitory transmitter
    ¾ïÁ¦Àü´Þ¹°
  • inhibitory postsynaptic potential
    ¾ïÁ¦½Ã³ÀÈÄÀüÀ§, ¾ïÁ¦¿¬Á¢ÈÄÀüÀ§
  • atypical lymphocyte
    ºñÀüÇü¸²ÇÁ±¸
  • lymphocyte-activating determinant
    ¸²ÇÁ±¸È°¼º°áÁ¤±â
  • effector lymphocyte
    ÀÛµ¿¸²ÇÁ±¸
  • killer lymphocyte
    ¼¼Æ÷µ¶¼º¸²ÇÁ±¸
  • lymphocyte
    ¸²ÇÁ±¸
  • leukocytoid lymphocyte
    ¹éÇ÷±¸¸ð¾ç¸²ÇÁ±¸
  • lymphocyte series
    ¸²ÇÁ±¸°è¿­
  • primed lymphocyte
    ÃÊȸ¹Î°¨¸²ÇÁ±¸
  • resident lymphocyte
    »óÁÖ¸²ÇÁ±¸
  • reticular lymphocyte
    ¸Á»ó¸²ÇÁ±¸
  • sensitized lymphocyte
    ¹Î°¨¸²ÇÁ±¸
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • primed lymphocyte
    ÃÊȸ°¨ÀÛ ¸²ÇÁ±¸
  • primed lymphocyte typing
    ÃÊȸÇ׿øÀÚ±ØÈÄ ¸²ÇÁ±¸Çüº°È­
  • primed lymphocyte-typing test
    ÃÊȸ°¨ÀÛ ¸²ÇÁ±¸ÀÌ¿ë Çüº°°Ë»ç
  • GIP (Gastric inhibitory peptide)
    À§Àå¾ïÁ¦(êÖíóåäð¤) ÆéŸÀ̵å
  • Gastric inhibitory peptide
    À§¾ïÁ¦(êÖåäð¤)È£¸£¸ó
  • Hypothalamic inhibitory hormones
    ½Ã»óÇϺξïÁ¦È£¸£¸ó
  • IPSP = inhibitory postsynaptic potential
    ¾ïÁ¦¼º(åäð¤àõ)½Ã³À½ºÈÄ(ý­)Àü¾Ð(ï³äâ)
  • inhibitory action
    ÀúÁöÀÛ¿ë(îÁò­íÂéÄ).
  • inhibitory autacoid
    ¾ïÁ¦¿À¿ÀŸÄÚÀ̵å.
  • inhibitory concentration, minimum (MIC)
    ¾ïÁ¦ÃÖ¼Ò³óµµ
  • inhibitory effect
    ¾ïÁ¦È¿°ú(åäð¤ Íý).
  • inhibitory effect
    ¾ïÁ¦È¿°ú.
  • inhibitory enzyme
    ÀúÇØÈ¿¼Ò.
  • inhibitory hormone
    ¾ïÁ¦(åäð¤)È£¸£¸ó.
  • inhibitory junctional potential
    ¾ïÁ¦¼º Á¢ÇÕºÎÀü¾Ð(ïÈùêݬï³äâ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • inhibitory effect
    ¾ïÁ¦È¿°ú(åäð¤ Íý).
  • inhibitory enzyme
    ÀúÇØÈ¿¼Ò.
  • inhibitory hormone
    ¾ïÁ¦(åäð¤)È£¸£¸ó.
  • inhibitory junctional potential
    ¾ïÁ¦¼º Á¢ÇÕºÎÀü¾Ð(ïÈùêݬï³äâ).
  • inhibitory nerve
    ¾ïÁ¦½Å°æ.
  • inhibitory nerve
    ¾ïÁ¦½Å°æ(åäð¤ãêÌè).
  • inhibitory postsynaptic potential
    ¾ïÁ¦¼º ½Ã³³½ºÈÄÀü¾Ð.
  • inhibitory postsynaptic potential
    ¾ïÁ¦¼º ½Ã³³½ºÈÄ Àü¾Ð
  • inhibitory postsynaptic potential = IPSP
    ¾ïÁ¦¼º ½Ã³³½ºÈÄÀü¾Ð.
  • inhibitory synapse
    ¾ïÁ¦¼º ½Ã³³½º.
  • inhibitory synapse
    ¾ïÁ¦¼º(åäð¤àõ) ½Ã³³½º.
  • inhibitory transmitter
    ¾ïÁ¦¼º Àü´Þ¹°Áú.
  • inhibitory zone
    ¾ïÁ¦¹üÀ§(åäð¤ÛôêÌ).
  • minimal inhibitory concentration
    ÃÖÀú¹ßÀ°ÀúÁö³óµµ(õÌî¸Û¡ëÀðæò­ÒØöô).
  • minimum inhibitory concentration
    ÃÖ¼Ò¹ßÀ°ÀúÁö³óµµ(õÌá³Û¡ëÀîÁò­ÒØöô).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • anti-egg-white injury factor
    Ç׳­¹é ¼Õ»óÀÎÀÚ(ù÷ÑëÛÜáßß¿ì×í­)
  • anti-fatty-liver-factor
    Ç×Áö¹æ°£ÀÎÀÚ(ù÷ò·Û¸ÊÜì×í­)
  • anti-gray-hair factor
    Ç×¹é¸ð¹ß ÀÎÀÚ(ù÷ÛÜÙ¾Û¥ì×í­)
  • antiacrodynia factor
    Ç×Áö´Üµ¿Åë ÀÎÀÚ(ù÷ò¶Ó®ÔÙ÷Ôì×í­)
  • antianemia factor
    Ç׺óÇ÷ÀÎÀÚ(ù÷Þ¸úìì×í­)
  • antiberiberi factor
    Ç×°¢±âÀÎÀÚ(ù÷ÊÅѨì×í­)
  • antiblack-tongue factor
    Ç×Èæ¼³ÀÎÀÚ(ù÷ýÙàßì×í­)
  • antihemophilic factor
    Ç×Ç÷¿ìº´ÀÎÀÚ(ù÷úìéÒÜ»ì×í­)
  • antihemophilic factor B
    Ç×Ç÷¿ìº´ÀÎÀÚ (ù÷úìéÒÜ»ì×í­) B
  • antihemophilic factor C
    Ç×Ç÷¿ìº´ÀÎÀÚ (ù÷úìéÒÜ»ì×í­) C
  • antineuritic factor
    Ç׽Ű漺ÀÎÀÚ(ù÷ãêÌèàõì×í­)
  • antinuclear factor
    Ç×ÇÙÀÎÀÚ(ù÷ú·ì×í­)
  • antipellagra factor
    Ç×(ù÷)Æç¶ó±×¶ó ÀÎÀÚ(ì×í­)
  • antipeptic ulcer factor
    Ç×(ù÷)±Ë¾ç(Ï÷åË) ÀÎÀÚ(ì×í­)
  • antipernicious anemia factor
    Ç×(ù÷)¾Ç¼ººóÇ÷(äÂàõÞ¸úì) ÀÎÀÚ(ì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PAF paroxysmal atrial fibrillation; peroxisomal assembly factor; phosphodiesterase-activating factor; pl...
SF Sabin-Feldman [test]; safety factor; salt-free; scarlet fever; screen film; seminal fluid; serosal f...
TF free thyroxine; tactile fremitus; tail flick [reflex]; temperature factor; testicular feminization; ...
PIF   1) Proliferation Inhibitory Factor
  2) Prolactin release Inhibiting Factor...
LIA Laser Institute of America; leukemia-associated inhibitory activity; lock-in amplifier; lymphocyte-i...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LIF Leukaemia Inhibitory Factor
MIF Migration Inhibitory Factor
NIF Neutrophil inhibitory factor
OCIF OPG)-osteoclastogenesis-inhibitory factor
OCIF Osteoclastogenesis inhibitory factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • marrow lymphocyte
    °ñ¼ö ¸²ÇÁ±¸
  • mixed lymphocyte culture
    È¥ÇÕ ¸²ÇÁ±¸ ¹è¾ç
  • monocyte lymphocyte ratio
    ´Ü±¸ ¸²ÇÁ±¸ºñ
  • small lymphocyte
    ÀÛÀº ¸²ÇÁ±¸, ¼Ò¸²ÇÁ±¸
  • thymus-derived lymphocyte
    Èä¼± À¯·¡ Àӯı¸
  • central inhibitory connection
    ÁßÃß ¾ïÁ¦ ¿¬°á
  • descending inhibitory system
    ÇÏÇà ¾ïÁ¦°è
  • inhibitory
    ¾ïÁ¦¼º
    °úÁ¤À» ¾ïÁ¦ ¶Ç´Â ÀúÁöÇÏ´Â. ºÎºÐÀûÀ¸·Î ¶Ç´Â ¿ÏÀüÈ÷ Á¤Ã¼, Á¤Áö½ÃŰ´Â.
  • inhibitory afferent input
    ¾ïÁ¦¼º ±¸½É¼º ÀÔ·Â
  • inhibitory contribution
    ¾ïÁ¦¼º ºÐÆ÷
  • inhibitory hormone
    ¾ïÁ¦ È£¸£¸ó
    Ç¥Àû ±â°ü¿¡ ´ëÇÏ¿© ¾ïÁ¦ÀûÀ¸·Î ÀÛ¿ëÇϴ ȣ¸£¸ó.
  • inhibitory input
    ¿ªÁ¦¼º ÀÔ·Â
  • inhibitory interneuron
    ¾ïÁ¦ °³Àç ´º¿ì·±
  • inhibitory output cell
    ¾ïÁ¦ Ãâ·Â ¼¼Æ÷
  • inhibitory postsynaptic potential
    ¾ïÁ¦¼º ½Ã³³½ºÈÄ Àü¾Ð
    ¾ïÁ¦¼º ±¸½É·Î¿¡ ÀÏÁ¦È÷ Ãæµ¿ÀÌ °¡ÇØÁú ¶§ ½Ã³À½º ÈÄ ´º·Ð¿¡ ¹ßÇàÇÏ´Â ¸·ÀüÀ§ÀÇ Àϰú¼º °úºÐ±ØÀ̸ç, ÀÌ ¶§¹®¿¡ ½Å°æ ´ÜÀ§ÀÇ ¹ÝÀÀ¼ºÀÌ °¨¾àµÈ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
leukocyte migration-inhibitory factors Protein factor(s) released by sensitised lymphocytes (and possibly other cells) that inhibit the movement of leukocytes, especially polymorphonuclear cells, away from their site of release. Assays for these factors are used as tests for cellular immunity. Two of the common assays are the leukocyte migration capillary tube technique (lmct) and the leukocyte migration agarose technique (lmat).
(12 Dec 1998)
antigens, differentiation, b-lymphocyte Membrane antigens associated with maturation stages of B-lymphocytes, often expressed in tumours of B-cell origin.
(12 Dec 1998)
antigens, differentiation, t-lymphocyte Antigens expressed on the cell membrane of T-lymphocytes during differentiation, activation, and normal and neoplastic transformation. Their phenotypic characterization is important in differential diagnosis and studies of thymic ontogeny and T-cell function.
(12 Dec 1998)
bare lymphocyte syndrome <syndrome> Absence of HLA antigens on peripheral mononuclear cells, which may result in immunodeficiency.
(05 Mar 2000)
B lymphocyte <haematology, immunology> An immunologically important lymphocyte, produced by the bone marrow, that is responsible for the production of immunoglobulins, it is the precursor of the plasma cell.
The surface markers can be used to detect and differentiate chronic lymphocytic leukaemia from acute lymphocytic leukaemia.
(13 Nov 1997)
b-lymphocyte subsets A classification of B-lymphocytes based on structurally or functionally different populations of cells.
(12 Dec 1998)
gene rearrangement, b-lymphocyte Ordered rearrangement of b-lymphocyte variable gene regions coding for the immunoglobulin chains, thereby contributing to antibody diversity. It occurs during the differentiation of the immature b-lymphocyte.
(12 Dec 1998)
gene rearrangement, b-lymphocyte, heavy chain Ordered rearrangement of b-lymphocyte variable gene regions thereby contributing to antibody diversity. It occurs during the first stage of differentiation of the immature b-lymphocyte.
(12 Dec 1998)
gene rearrangement, b-lymphocyte, light chain Ordered rearrangement of b-lymphocyte variable gene regions coding for the kappa or lambda light chains, thereby contributing to antibody diversity. It occurs during the second stage of differentiation of the immature b-lymphocyte.
(12 Dec 1998)
gene rearrangement, t-lymphocyte Ordered rearrangement of T-cell variable gene regions coding for the antigen receptors.
(12 Dec 1998)
receptors, lymphocyte homing Cell surface glycoproteins on lymphocytes and other leukocytes that mediate adhesion to specialised blood vessels called high endothelial venules. Several different classes of lymphocyte homing receptors have been identified, and they appear to target different surface molecules (addressins) on high endothelial venules in different tissues. The adhesion plays a crucial role in the trafficking of lymphocytes.
(12 Dec 1998)
virgin lymphocyte <haematology, immunology> A lymphocyte that has not and whose precursors have not, encountered the antigenic determinant for which it possesses receptors.
(18 Nov 1997)
CD4 lymphocyte A specific type of lymphocyte, derived from the thymus gland, that plays an important role in cellular immunity. T4 lymphocytes (CD4 cells) are decreased (absolute counts less than 200) in patients with AIDS resulting in compromised immune function.
(27 Sep 1997)
CD4 lymphocyte count A count of the number of CD4-positive lymphocytes in the blood. Determination requires the use of a fluorescence-activated flow cytometer.
(12 Dec 1998)
Rieder's lymphocyte An abnormal form of lymphocyte that has a greatly indented (or lobed), slightly twisted nucleus; such cells are usually observed in certain examples of chronic lymphocytic leukaemia.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • nerve growth factor
    (»ý¸®)½Å°æ ¼ºÀåÀÎÀÚ(Áö°¢(±³°¨)½Å°æ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÀÚ±ØÇÏ´Â ´Ü¹éÁú)
  • noise factor(figure)
    (ÁõÆø±â¿¡¼­ÀÇ)ÀâÀ½Áö¼ö
  • pp factor
    Ç× Æç¶ó±×¶ó ÀÎÀÚ(Æç¶ó±×¶ó ¿¹¹æ¿¡ ¾²´Â ´ÏÄÚÆ¾»ê,´ÏÄÚÆ¾»ê¸¶À̵å)
  • prime factor
    ¼ÒÀμö
  • releasing factor
    È£¸£¸ó ¹æÃâÀÎÀÚ
  • rheumatoid factor
    ·ù¸ÓƼÁòÀÎÀÚ(¸¸¼º °üÀý ·ù¸ÓƼÁò ȯÀÚÀÇ ÀÚ±â Ç×ü)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á